Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ERG
REST API REST API
Homo sapiens
ERG is differentially expressed in 254 experiments: 159 organism parts: lung, blood, ... (157 more);, 226 disease states: normal, lung adenocarcinoma, ... (224 more);, 89 cell types 215 cell lines 21 compound treatments and 81 other conditions.
Synonyms p55, erg-3
Orthologs Erg (Mus musculus)   ERG_CHICK (Gallus gallus)   erg (Danio rerio)   F6S5C8_CIOIN (Ciona intestinalis)   ERG (Bos taurus)   F6YFK6_CIOIN (Ciona intestinalis)   Q4H3K3_CIOIN (Ciona intestinalis)   Erg (Rattus norvegicus)   erg (Xenopus laevis)   ERG (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, cytoplasm, cell proliferation, ribonucleoprotein complex, signal transducer activity, sequence-specific DNA binding, multicellular organismal development, nucleus, signal transduction, sequence-specific DNA binding transcription factor activity, protein phosphorylation
InterPro Term Ets, Pointed_dom
UniProt Accession P11308, A8MZ24, B5MDW0, A8MX39, Q16031, B4DVX5, B4E3C5
Gene-Disease Assocation EWING SARCOMA; ES
Search EB-eye ENSG00000157554
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-MEXP-433, ... (34 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-1309, E-GEOD-19639, E-GEOD-847, E-GEOD-18005, ... (24 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
MCF-10A
2
E-TABM-420, E-GEOD-14990
MOLT4
2
E-MTAB-37, E-MTAB-62
A172
1
1
E-MTAB-37
647V
1
1
E-MTAB-37
SNU423
1
E-MTAB-37
209 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-13909, ... (44 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-GEOD-19069, E-AFMX-5
CD34+
2
E-AFMX-5, E-TABM-145
hematopoietic stem cell
2
E-MEXP-872, E-MEXP-1403
primary T lymphocytes
1
E-GEOD-13909
germ cell
1
E-MTAB-25
ADC
1
1
E-GEOD-19188
83 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (61 experiments)

Factor Value U/D Experiments
melanoma
3
E-MTAB-62, E-GEOD-7307, E-MTAB-37
lung adenocarcinoma
1
3
E-MTAB-37, E-GEOD-2514, E-MEXP-231, E-MTAB-62
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MTAB-62, E-MEXP-66
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-1729
colon carcinoma
2
E-MTAB-62, E-MTAB-37
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
220 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-1417, E-GEOD-697, E-TABM-782, E-GEOD-15811, ... (14 experiments)

Factor Value U/D Experiments
none
3
5
E-GEOD-412, E-GEOD-2803, E-GEOD-7400, E-GEOD-5099, E-GEOD-5418, ... (8 experiments)
U0126
1
1
E-GEOD-697
camptothecin
1
E-GEOD-1417
BCR/ABL1
1
1
E-GEOD-15811
Cxcl12
1
1
E-GEOD-7307
unknown
1
E-GEOD-7307
15 more value(s).


Age at diagnosis

studied in E-GEOD-21653, E-GEOD-4922

Factor Value U/D Experiments
84
2
1
E-GEOD-21653
78 years
1
1
E-GEOD-4922
86 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-860, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1638, E-MEXP-2359, E-GEOD-6236, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-MEXP-149, E-GEOD-2466, E-GEOD-17476, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-20504, E-MEXP-1446, E-GEOD-9764, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MEXP-2069, E-TABM-15, E-GEOD-3606, E-GEOD-20876, ... (32 experiments)

Infection
studied in E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-1493, E-GEOD-22309, E-GEOD-1460, E-GEOD-17636, E-GEOD-7114, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-21521

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Stimulus or stress
studied in E-GEOD-7538

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4271, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922

Processing time: 0.292 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM